Multimeric constructs

Details Multimeric constructs Multimeric constructs

2011-04-19

2011-04-19

Allen, Marianne P (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S069700, C435S212000, C435S320100, C536S023400, C530S350000, C514S001000

Reexamination Certificate

active

07928072

ABSTRACT:
Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.

REFERENCES:
patent: 5089833 (1992-02-01), Takahashi et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5155027 (1992-10-01), Sledziewski et al.
patent: 5336603 (1994-08-01), Capon
patent: 5567584 (1996-10-01), Sledziewski et al.
patent: 5712380 (1998-01-01), Kendall et al.
patent: 5827702 (1998-10-01), Cuthbertson
patent: 5843725 (1998-12-01), Sledziewski et al.
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6204011 (2001-03-01), Kendall et al.
patent: 6270993 (2001-08-01), Shibuya et al.
patent: 6348333 (2002-02-01), Niwa et al.
patent: 6375929 (2002-04-01), Thomas, Jr. et al.
patent: 6378526 (2002-04-01), Bowman et al.
patent: 6383486 (2002-05-01), Davis-Smyth et al.
patent: 6397849 (2002-06-01), Bowman et al.
patent: 6482634 (2002-11-01), Wilson et al.
patent: 6686200 (2004-02-01), Dong
patent: 6821775 (2004-11-01), Kovesdi et al.
patent: 6897294 (2005-05-01), Davis-Smyth et al.
patent: 6943019 (2005-09-01), Wilson et al.
patent: 6943153 (2005-09-01), Manning, Jr. et al.
patent: 7083950 (2006-08-01), Stahl et al.
patent: 7087411 (2006-08-01), Daly et al.
patent: 2002/0098187 (2002-07-01), Ferrara et al.
patent: 2003/0092604 (2003-05-01), Davis-Smyth et al.
patent: 2004/0052785 (2004-03-01), Goodman et al.
patent: 2005/0163798 (2005-07-01), Papadopoulos et al.
patent: 2005/0175624 (2005-08-01), Romero et al.
patent: 2006/0134111 (2006-06-01), Agarwal
patent: 2006/0193830 (2006-08-01), Hauswirth et al.
patent: 0928203 (1999-07-01), None
patent: 1238986 (2002-09-01), None
patent: 1621213 (2006-02-01), None
patent: WO9108298 (1991-06-01), None
patent: WO9410202 (1994-05-01), None
patent: WO9421679 (1994-09-01), None
patent: WO9506743 (1995-03-01), None
patent: WO9613276 (1996-05-01), None
patent: WO 98/13071 (1998-04-01), None
patent: WO9831794 (1998-07-01), None
patent: WO 98/51323 (1998-11-01), None
patent: WO9855638 (1998-12-01), None
patent: WO9858053 (1998-12-01), None
patent: WO0054813 (2000-09-01), None
patent: WO0075319 (2000-12-01), None
patent: WO0224234 (2002-03-01), None
patent: WO03080648 (2003-10-01), None
patent: WO/2004085478 (2004-10-01), None
patent: WO2006066086 (2006-06-01), None
Kendall, R.L. and Thomas, K.A., “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor”, Proc. Natl. Acad. Sci. USA, 90:10705-10709, Nov. 1993.
Wiesmann, C. et al., “Crystal Structure at 1.7 A Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor”, Cell, 91:695-704, Nov. 28, 1997.
Holash, J. et al., “VEGF-Trap: A VEGF blocker with potent antitumor effects”, Proceeding of the National Academy of Sciences of USA, 99(17):11393-11398, Aug. 20, 2002.
Vangelista, L. et al., “A minimal receptor-Ig chimera of human FcepsilonRl alpha-chain efficiently binds secretory and membrane IgE”, Protein Engineering, 15(1):51-57, Jan. 2002.
Olafsen, T. et al., “Characterization of engineered anti-p185HER-2 (scFv-CH3) 2 antibody fragments (minibodies) for tumor targeting”, Protein Engineering Design & Selection, 17(4):315-323, Apr. 2004.
Hu, S-Z et al., “Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-chain FV-CH3) which Exhibits Rapid, High-Level Targeting of Xenografts”, Cancer Research, 56(13):3055-3061, Jul. 1, 1996.
Afanasieva T.A. et al., “Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy”, Gene Therapy, 10(21):1850-1859, Oct. 1, 2003.
Lai, Yky et al., “Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy”, Gene Therapy, 9:804-813, 2002.
Mori, K. et al., “AAV-Mediated Gene Transfer of Pigment Epithelium-Derived Factor Inhibits Choroidal Neovascularization”, Investigative Opthalmology & Visual Science, 43(6):1994-2000, Jun. 2002.
Campochiaro, Peter A., “Gene therapy for retinal and choroidal diseases”, Expert Opin. Biol. Ther., 2(5):537-544, 2002.
Chaum, E. and Hatton, M.P., “Gene Therapy for Genetic and Acquired Retinal Diseases”, Survey of Opthalmology, 47(5):449-469, Sep.-Oct. 2002.
Borras, Teresa, “Recent developments in ocular gene therapy”, Experimental Eye Research, 76:643-652, 2003.
Pleyer, U. and Ritter, T., “Gene therapy in immune-mediated diseases of the eye”, Progress in Retinal and Eye Research, 22:277-293, 2003.
Jomary, C. et al., “Adenoassociated Virus Vector-Mediated Gene Transfer to Retinal Cells In Vitro and In Vivo”, Investigative Ophthalmology & Visual Science, 36(4):Abstract 3569-556, Mar. 15, 1995.
Ali, R.R. et al., “Gene transfer into the mouse retina mediated by an adeno-associated viral vector”, Human Molecular Genetics, 5(5):591-594, 1996.
Hauswirth, W. et al., “Efficient Photoreceptor-Targeted Gene Expression In Vivo Mediated By Recombinant Adeno-Associated Virus”, Investigative Ophthalmology & Visual Science, 38(4): Abstract 1193-5:45, Mar. 15, 1997.
Bennett, J. et al., “Real-Time, Noninvasive In Vivo Assessment of Adeno-Associated Virus-Mediated Retinal Transduction”, Investigative Ophthalmology & Visual Science, 38:(13):2857-2863, Dec. 1997.
Ali, R.R. et al., “Adeno-Associated Virus Gene Transfer to Mouse Retina”, Human Gene Therapy, 9:81-86, Jan. 1, 1998.
Bennett, J. et al., “Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina”, Proc. Natl. Acad. Sci., USA, 96:9920-9925, Aug. 1999.
Auricchio, A. et al., “Inhibition of Retinal Neovascularization by Intraocular Viral-Mediated Delivery of Anti-angiogenic Agents”, Molecular Therapy, 6(4):490-494, Oct. 2002.
Bok, Dean, “Retinal Transplantation and Gene Therapy”, Investigative Ophthalmology & Visual Science, 34(3):473-476, Mar. 1993.
Zack, Donald J., “Ocular Gene Therapy From Fantasy to Forseeable Reality”, Arch Ophthalmology, 111:1477-1478, Nov. 1993.
Bennett, J., “Immune response following introcular delivery of recombinant viral vectors”, Gene Therapy, 10:977-982, 2003.
National Institutes of Health Recombinant DNA Advisory Committee (RAC Meeting) Sep. 6-7, 2001, Meeting Agenda, Human Gene Therapy 12:2021-2032, Nov. 1, 2001.
Mashhour, B. et al., “In vivo adenovirus-mediated gene transfer into ocular tissues”, Gene Therapy, 1:122-126, 1994.
Li, T. et al., “In Vivo Transfer of a Reporter Gene to the Retina Mediated by an Adenoviral Vector”, Investigative Ophthalmology & Visual Science, 35(5):2543-2549, Apr. 1994.
Jomary, C. et al., “Adenovirus-mediated gene transfer to murine retinal cells in vitro and in vivo”, FEBS Letters, 347:117-122, 1994.
Bennett, J. et al., “Adenovirus Vector-Mediated In Vivo Gene Transfer Into Adult Murine Retina”, Investigative Ophthalmology & Visual Science, 35(5):2535-2542.
Mahasreshti, P.J. et al., “Adenovirus-mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma”, Clinical Cancer Research, 7:2057-2066, Jul. 2001.
Dejneka, NS et al., “Pharmacologically regulate

Affiliated with

Also associated with

Rating

Multimeric constructs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multimeric constructs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multimeric constructs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2619019